High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
about
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysisType 2 Diabetes and ADP Receptor Blocker TherapyPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsThe prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysisHigh residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceEvidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Aspirin and clopidogrel resistance: consideration and managementPlatelet function in whole-blood donors is impaired: the effects of painkillersEvaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC studyInterplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjectsHostility and platelet reactivity in individuals without a history of cardiovascular disease events.Clinical importance of aspirin and clopidogrel resistanceAn algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.Platelet hyperreactivity: predictive and intrinsic propertiesImpaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort studyAZD6140.Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoproteinClopidogrel resistance--the cardiologist's perspective.Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.Current concepts about inhibition of platelet aggregation.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoRecent developments in clopidogrel pharmacology and their relation to clinical outcomes.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonistP2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.Platelet reactivity and nonresponse to dual antiplatelet therapy: a review.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy: First experiences.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization.Antiplatelet therapy and vascular disease: an update.
P2860
Q22242057-E5AFF1AD-57B1-408E-88F5-38C38DA382A7Q26772996-EB937AE0-39F4-4791-AE04-EE7DDF2B0B8FQ26775125-265C1A3F-6E6D-4702-85FD-ED33D3580708Q26824694-FEEE7D59-84E3-4C1E-AD9B-AA2ABF82AA4EQ26824850-7805F703-C580-42B1-98A5-C54A5C09E7DCQ28200552-6BCDE1EB-BBC1-4BB6-B804-AA63B60CF88FQ28200610-D8BF0F4D-9543-481C-99ED-FA7551909C70Q28213918-FB90D031-B282-46C7-83D3-D08E2108E3BFQ28221921-97D5C917-BD36-406E-BEC5-C9EEC2337475Q33516375-ACAED116-CB59-43DE-96C7-A180A0B20A7BQ33569289-368FD54A-63B9-417B-AEB0-C7407FC869DFQ33893919-FC950C18-6839-4B38-A188-035196E154D3Q33933475-8E4EAA9A-E3F3-411C-A522-9489C5F226D5Q34186272-F43E3B6E-1A85-4A22-9AF0-D3FDC67E0AA7Q34211191-CD747F87-53B2-4EF7-B545-782256CECA34Q34390050-0D76CB61-2475-4F16-BF0E-C00B4D347716Q34577974-8BF36881-9C08-43FF-B1BE-81FEEB0DEBD3Q35019665-D50B752B-C42A-4BCF-8FDF-A579C55881B8Q35208684-1CA7700E-836B-47D6-AAB9-8C342541A6CBQ35985453-8FA2B9A7-4BA8-4417-A156-20F18930E084Q36002765-AB0A97B3-6ACB-4B9E-9DBC-04430D661274Q36045746-04A8720B-4B76-4F08-9C23-13135EE1F6FDQ36715768-75BC69E2-3223-44DE-9EA5-E8795C588368Q36790211-E9586BAE-CD58-427C-8B65-06E076BCC9C6Q36819608-38A2D80C-FC6E-4BFE-9C60-EA5149E71210Q36822610-B53E427A-1923-46C4-A94E-AC9C4D086939Q37326634-131158EA-73EE-4C6A-ACB4-FAF8377E7ECCQ37378896-2B7F84DA-1B2C-433A-8C6E-049DDD2586DCQ37540088-150D54ED-3B7E-44BB-9D94-09D146865336Q37550156-A6416723-7F46-4A81-896C-8998C77F8417Q37552005-6E863F41-4E77-4F7F-B9DE-5214F67C5A4DQ37562606-58E1B1B8-59E8-4A3D-A0AB-5F588A000F17Q37608580-1265208B-F3D9-448A-A9E4-B4C5F6AC96B8Q37618798-7FB7930F-9A07-4739-9538-2E62687327EDQ37641606-185F7494-7065-46CA-9ECD-5C5276BB71C1Q37646648-7207E149-789E-4900-B1BE-74B2C6D58F2CQ37693951-FA00545F-6DCD-4D9F-8588-5283C132004EQ37752222-C142B743-3E56-48E3-8CCA-E05080966F52Q37765291-58D5A3FA-EE00-4660-8E71-B6B35CA90428Q37838100-C49F0079-C7D2-4FAD-8CD1-8AA3DA6862EC
P2860
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High post-treatment platelet r ...... ng for acute coronary syndrome
@ast
High post-treatment platelet r ...... ng for acute coronary syndrome
@en
High post-treatment platelet r ...... ng for acute coronary syndrome
@nl
type
label
High post-treatment platelet r ...... ng for acute coronary syndrome
@ast
High post-treatment platelet r ...... ng for acute coronary syndrome
@en
High post-treatment platelet r ...... ng for acute coronary syndrome
@nl
prefLabel
High post-treatment platelet r ...... ng for acute coronary syndrome
@ast
High post-treatment platelet r ...... ng for acute coronary syndrome
@en
High post-treatment platelet r ...... ng for acute coronary syndrome
@nl
P2093
P2860
P3181
P1476
High post-treatment platelet r ...... ng for acute coronary syndrome
@en
P2093
J-L Bonnet
M-C Alessi
P E Morange
P2860
P3181
P356
10.1111/J.1538-7836.2005.01751.X
P407
P577
2006-03-01T00:00:00Z